Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16702786 | 0.86 | ACACB (0.38) | ELANEAKR1C3AKR1C2ACACBMAPT | |
| SCHEMBL2286310 | 0.85 | ELANE (0.41) | ELANEAKR1C3AKR1C2ACACBMAPT | |
| SCHEMBL3239401 | 0.83 | ELANE (0.39) | ELANEAKR1C3AKR1C2ACACBMAPT | |
| SCHEMBL15967815 | 0.83 | ELANE (0.46) | ELANELMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL15984582 | 0.83 | LMNA (0.52) | ELANEMAPTLMNAMEN1KMT2A | |
| SCHEMBL15967813 | 0.83 | ELANE (0.46) | ELANELMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL15984566 | 0.83 | LMNA (0.52) | ELANEMAPTLMNAMEN1KMT2A | |
| SCHEMBL16003903 | 0.81 | ELANE (0.45) | ELANEMAPTLMNANPSR1MEN1 | |
| SCHEMBL16003600 | 0.81 | ELANE (0.45) | ELANEMAPTLMNANPSR1MEN1 | |
| SCHEMBL15967723 | 0.81 | ELANE (0.45) | ELANEMAPTKDM4ELMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516023-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2026-01-06 | — | — | US | disclosed |
| EP-4001272-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2024-11-13 | — | — | EP | disclosed |
| EP-4001272-A1 | NMDA ANTAGONIST PRODRUGS | Astrazeneca AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| EP-3564234-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2021-09-29 | — | — | EP | disclosed |
| US-20210040039-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2021-02-11 | — | — | US | disclosed |
| US-10815199-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2020-10-27 | — | — | US | disclosed |
| CN-111187202-A | NMDA antagonist prodrugs | 阿斯利康(瑞典)有限公司 | 2020-05-22 | — | — | CN | disclosed |
| CN-105683180-B | NMDA antagonist prodrugs | 阿斯利康(瑞典)有限公司 | 2020-01-21 | — | — | CN | disclosed |
| EP-3564234-A1 | NMDA ANTAGONIST PRODRUGS | AstraZeneca AB (SE) | 2019-11-06 | — | — | EP | disclosed |
| US-20190152914-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2019-05-23 | — | — | US | disclosed |
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100081830-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | XENOPORT, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081830-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | XENOPORT, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081830-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | XENOPORT, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2010017498-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | XENOPORT, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017504-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017498-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | XENOPORT, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017504-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | XENOPORT, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087667-A1 | METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS | CPS1, ASNS, NAAA | ELANE 1960/4885AKR1C3 466/4885AKR1C2 585/4885 |
| US-20210040039-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885AKR1C3 3604/4885AKR1C2 3547/4885 |
| US-20100081830-A1 | METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES | CPS1, SI, ASNS | ELANE 1609/4885AKR1C3 412/4885AKR1C2 433/4885 |
| US-10815199-B2 | NMDA antagonist prodrugs | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885AKR1C3 3604/4885AKR1C2 3547/4885 |
| US-20190152914-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | ELANE 2956/4885AKR1C3 3604/4885AKR1C2 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.